clinical trial · NCT01596400
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years
Kyowa Kirin Pharmaceutical Development Ltd·phase1·completed·n = 19
Chemotherapy Induced Nausea and Vomitinggranisetron transdermal systemGranisetron IV
brief summary
The purpose of this study is to determine the dosing strategy for adolescents aged 13 to 17 years.
started
May 1, 2012
primary completion
Aug 1, 2015
completion
Dec 1, 2016
last updated
Jun 17, 2024
official title
An Open-label, Cross-over, Pharmacokinetic Study to Assess the Safety and Pharmacokinetics of Transdermal Granisetron (Sancuso® Patch) and IV Granisetron in a Pediatric Oncology Population (Aged 13 to 17 Years)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol